Table 2.
Patients who developed an increase in their antiporcine factor VIII inhibitor titer after exposure to recombinant B-domain-deleted porcine factor VIII.
| Patient ID | 1 | 2 | 3 |
|---|---|---|---|
| Baseline antiporcine FVIII titer (pBU/mL) | 13 | 4 | 2 |
| Baseline anti-hFVIII titer (BU/mL) | 384 | 563 | 309 |
| Time to first increase of antiporcine FVIII (d) | 15 | 15 | 10 |
| Time to first increase of anti-hFVIII (d) | No increase | 36 | 10 |
| Titer of anti-hFVIII post exposure (BU/mL) | 346 | 666 | 393 |
| Titer of antiporcine FVIII post exposure (pBU/mL) | 29 | 7 | 4 |
| Percentage of increase in antiporcine FVIII titer (%) | 123 | 75 | 100 |
BU, Bethesda Units; FVIII, factor VIII; hFVIII, human factor VIII.